Researchers aim identify the root causes of drug-induced diabetes among cancer patients, and then to develop new therapeutic strategies for preventing diabetic complications.
Transplant surgeons at two US hospitals are about to do something long considered taboo: put kidneys from donors with hepatitis C into recipients without the infection.
The intellectual property is secure. The science is sound. You’re about to make your pitch for funding. The scary next step for a biotech entrepreneur? Picking a company name.
A huge federal trial of personalized cancer medicine has run into an unexpected roadblock: Many of the tumor samples aren’t robust enough to be put through genetic analysis.
USEFUL LINKS
CONTACT
elie@eliedolgin.com
Contact Us
Thank you for contacting us. We will get back to you as soon as possible.
Oops, there was an error sending your message. Please try again later.